कंपनी का अवलोकन
BioRestorative Therapies, Inc. (BRTX) is a specialized biotechnology firm dedicated to developing therapeutic products and medical therapies that utilize cell and tissue protocols, with a primary focus on adult stem cells. The company operates within the healthcare sector, specifically targeting the biotechnology industry, where it seeks to advance treatments for conditions such as disc and spine disease as well as metabolic disorders. At the current scale, the enterprise holds a market capitalization of $6.11M and employs a workforce of 13 individuals, reflecting a small-cap, early-stage operational footprint. The annual revenue generated over the trailing twelve months stands at $359,700, figures which indicate that the company functions as a micro-cap entity with limited revenue generation relative to its peers in the broader biotechnology landscape.
वित्तीय स्वास्थ्य
The company reported a trailing twelve-month revenue of $359,700, yet it posted a net income of -$14,241,975 and an EBITDA of -$15,437,147, revealing a substantial gap between top-line activity and profitability that points to significant operating expenses and costs of goods sold eroding value. The firm generated free cash flow of -$6,200,023, indicating a negative cash conversion that suggests the company is currently burning cash to fund its research and development activities rather than generating liquidity from operations. Gross margin stands at an impressive 93.4%, which implies high gross efficiency in production or service delivery, whereas the operating margin of -19,516.8% and profit margin of 0.0% demonstrate that overhead costs and general expenses are disproportionately high compared to sales volume. The company holds cash reserves of $2.95M against a total debt obligation of $42,282, resulting in a debt-to-equity ratio of 11.85, which signifies a highly leveraged capital structure relative to equity despite the low absolute debt figure. The current ratio is 0.84, suggesting that current assets are insufficient to cover current liabilities without the sale of long-term assets or external financing. Furthermore, the return on equity is -320.5% and the return on assets is -119.6%, metrics that reveal that management's current strategies are effectively destroying shareholder value and utilizing assets inefficiently in terms of generating positive returns.
मूल्यांकन आकलन
BioRestorative Therapies, Inc. presents a trailing P/E ratio of N/A due to its net losses, while the forward P/E is listed at -0.46, a metric that does not provide traditional valuation context but rather reflects the negative earnings projection. The price-to-book ratio is 6.15, indicating that the market values the company's equity at a significant premium over its book value, which is common in biotechnology firms where future potential is valued higher than current tangible assets. The price-to-sales ratio stands at 17.00, and the EV/EBITDA is -0.21, suggesting that valuation multiples are driven by speculative growth expectations rather than current cash flow generation or earnings power. The stock traded with a 52-week high of $2.04 and a 52-week low of $0.19, positioning the current market price within a wide trading range that reflects high volatility typical of micro-cap biotech stocks. The beta value is 0.27, indicating that the stock's price volatility is significantly lower than the broader market in isolation, though this low beta can sometimes mask the extreme risks associated with the company's binary development outcomes.
Growth & Income
The company experienced a revenue growth rate of -54.7% year-over-year, while earnings growth is marked as N/A due to the absence of prior period profitability, implying that the business is in a contraction phase regarding sales without a viable path to earnings expansion in the short term. As the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it retains all available earnings and cash reserves to reinvest into its pipeline of cell and tissue protocol therapies rather than distributing income to shareholders. The absence of a dividend yield confirms that the capital structure relies entirely on internal funding and external capital markets to sustain operations during this negative growth phase. Overall, the growth and income profile of BioRestorative Therapies, Inc. is characterized by negative revenue expansion, zero income distribution, and a financial structure focused exclusively on funding high-risk therapeutic development programs.